tetano
Editor, Senior Moderator
Am J Med Sci
. 2021 Jun 6;S0002-9629(21)00214-7.
doi: 10.1016/j.amjms.2021.06.001. Online ahead of print.
Evaluation of Modified ATRIA Risk Score in Predicting Mortality in Hospitalized Patients with COVID-19
Gonul Aciksari[SUP] 1 [/SUP], Gokhan Cetinkal[SUP] 2 [/SUP], Mehmet Kocak[SUP] 3 [/SUP], Yasemin Cag[SUP] 4 [/SUP], Adem Atici[SUP] 5 [/SUP], Lutfiye Nilsun Altunal[SUP] 6 [/SUP], Hasan Ali Barman[SUP] 7 [/SUP], Mehtap Aydın[SUP] 8 [/SUP], Betul Balaban Kocas[SUP] 9 [/SUP], Gulsum Cam[SUP] 10 [/SUP], Kader Gorkem Guclu[SUP] 11 [/SUP], Mustafa Caliskan[SUP] 12 [/SUP]
Affiliations
Abstract
As the Modified Anticoagulation and Risk Factors in Atrial Fibrillation Risk Score (M-ATRIA-RS) encompasses prognostic risk factors of novel coronavirus-2019 (COVID-19), it may be used to predict in-hospital mortality. We aimed to investigate whether M-ATRIA-RS was an independent predictor of mortality in patients hospitalized for COVID-19 and compare its discrimination capability with CHADS, CHA2DS2-VASc, and modified CHA2DS2-VASc (mCHA2DS2-VASc)-RS. A total of 1,001 patients were retrospectively analyzed and classified into three groups based on M-ATRIA-RS, designed by changing sex criteria of ATRIA-RS from female to male: Group 1 for points 0-1 (n=448), Group 2 for points 2-4 (n=268), and Group 3 for points ≥5 (n=285). Clinical outcomes were defined as in-hospital mortality, need for high-flow oxygen and/or intubation, and admission to intensive care unit. As the M-ATRIA-RS increased, adverse clinical outcomes significantly increased (Group 1, 6.5%; Group 2, 15.3%; Group 3, 34.4%; p <0.001 mortality for in-hospital). Multivariate logistic regression analysis showed that M-ATRIA-RS, malignancy, troponin increase, and lactate dehydrogenase were independent predictors of in-hospital mortality (p<0.001, per scale possibility rate for ATRIA-RS 1.2). In receiver operating characteristic (ROC) analysis, the discriminative ability of M-ATRIA-RS was superior to mCHA2DS2-VASc-RS and ATRIA-RS, but similar to that Charlson Comorbidity Index (CCI) score (AUC[SUB]M-ATRIA[/SUB] vs AUC[SUB]ATRIA[/SUB] Z-test=3.14 p=0.002, AUC[SUB]M-ATRIA[/SUB]vs. AUC[SUB]mCHA2DS2-VASc[/SUB] Z-test=2.14, p=0.03; AUC[SUB]M-ATRIA[/SUB]vs. AUC[SUB]CCI[/SUB] Z-test=1.46 p=0.14). M-ATRIA-RS is useful to predict in-hospital mortality among patients hospitalized with COVID-19. In addition, it is superior to the mCHA2DS2-VASc-RS in predicting mortality in patients with COVID-19 and is more easily calculable than the CCI score.
Keywords: ATRIA risk score; COVID-19; SARS-CoV-2; mortality; risk stratification.
. 2021 Jun 6;S0002-9629(21)00214-7.
doi: 10.1016/j.amjms.2021.06.001. Online ahead of print.
Evaluation of Modified ATRIA Risk Score in Predicting Mortality in Hospitalized Patients with COVID-19
Gonul Aciksari[SUP] 1 [/SUP], Gokhan Cetinkal[SUP] 2 [/SUP], Mehmet Kocak[SUP] 3 [/SUP], Yasemin Cag[SUP] 4 [/SUP], Adem Atici[SUP] 5 [/SUP], Lutfiye Nilsun Altunal[SUP] 6 [/SUP], Hasan Ali Barman[SUP] 7 [/SUP], Mehtap Aydın[SUP] 8 [/SUP], Betul Balaban Kocas[SUP] 9 [/SUP], Gulsum Cam[SUP] 10 [/SUP], Kader Gorkem Guclu[SUP] 11 [/SUP], Mustafa Caliskan[SUP] 12 [/SUP]
Affiliations
- PMID: 34107275
- DOI: 10.1016/j.amjms.2021.06.001
Abstract
As the Modified Anticoagulation and Risk Factors in Atrial Fibrillation Risk Score (M-ATRIA-RS) encompasses prognostic risk factors of novel coronavirus-2019 (COVID-19), it may be used to predict in-hospital mortality. We aimed to investigate whether M-ATRIA-RS was an independent predictor of mortality in patients hospitalized for COVID-19 and compare its discrimination capability with CHADS, CHA2DS2-VASc, and modified CHA2DS2-VASc (mCHA2DS2-VASc)-RS. A total of 1,001 patients were retrospectively analyzed and classified into three groups based on M-ATRIA-RS, designed by changing sex criteria of ATRIA-RS from female to male: Group 1 for points 0-1 (n=448), Group 2 for points 2-4 (n=268), and Group 3 for points ≥5 (n=285). Clinical outcomes were defined as in-hospital mortality, need for high-flow oxygen and/or intubation, and admission to intensive care unit. As the M-ATRIA-RS increased, adverse clinical outcomes significantly increased (Group 1, 6.5%; Group 2, 15.3%; Group 3, 34.4%; p <0.001 mortality for in-hospital). Multivariate logistic regression analysis showed that M-ATRIA-RS, malignancy, troponin increase, and lactate dehydrogenase were independent predictors of in-hospital mortality (p<0.001, per scale possibility rate for ATRIA-RS 1.2). In receiver operating characteristic (ROC) analysis, the discriminative ability of M-ATRIA-RS was superior to mCHA2DS2-VASc-RS and ATRIA-RS, but similar to that Charlson Comorbidity Index (CCI) score (AUC[SUB]M-ATRIA[/SUB] vs AUC[SUB]ATRIA[/SUB] Z-test=3.14 p=0.002, AUC[SUB]M-ATRIA[/SUB]vs. AUC[SUB]mCHA2DS2-VASc[/SUB] Z-test=2.14, p=0.03; AUC[SUB]M-ATRIA[/SUB]vs. AUC[SUB]CCI[/SUB] Z-test=1.46 p=0.14). M-ATRIA-RS is useful to predict in-hospital mortality among patients hospitalized with COVID-19. In addition, it is superior to the mCHA2DS2-VASc-RS in predicting mortality in patients with COVID-19 and is more easily calculable than the CCI score.
Keywords: ATRIA risk score; COVID-19; SARS-CoV-2; mortality; risk stratification.